Emory University

Other

University of Georgia Research Foundation, Inc.

Neurop, Inc.

The United States of America As Represented by the Secretary of

Imperial College of Science, Technology and Medicine

Yale University

Gilead Sciences, Inc.

Ortho Pharmaceutical Corporation

Georgia State University Research Foundation, Inc.

Mcneil Ab

Children's Healthcare of Atlanta, Inc.

Triangle Pharmaceuticals, Inc.

Dennis C. Liotta

George R. Painter

Dennis C Liotta

Raymond F Schinazi

Woo-Baeg Choi

James P Snyder

Michael G Natchus

Stephen F Traynelis

Donald G Stein

David Brian Guthrie

Iqbal Sayeed

Mark Andrew Lockwood

Lawrence J Wilson

George R Painter

Chung K Chu

Junxing Shi

Yongseok Choi

Alfred H Merrill, Jr

J Jeffrey McAtee

Kyeong Lee

Joon H Hong

Hariharan Venkatesan

Yesim Altas Tahirovic

Hyunsuk Shim

Kyle Giesler

Merrick R Almond

Abel De La Rosa

Gregory R Bluemling

Marcos Sznaidman

Darryl G Cleary

Edgars Jecs

Richard Arrendale

Michael W Hager

Yao Jing

Ketan Desai

Ethel Garnier

Raymond J Dingledine

John Wiseman

Elaine W Wang

Ronald T Riley

David Menaldino

Matthew C Davis

Brian Adams

Mamoru Shoji

Eva M Ferstl

Ustun B Sunay

Michael V Voronkov

Thomas E Keane

Laura Captain

Marcus A Schestopol

Jos&egrave; D Soria

Stephen Pelly

Zackery Will Dentmon

Susheng Wang

Weiqiang Zhan

Anthony G M Barrett

John W Mellors

Shuli Mao

John A Petros

Scott James Myers

Timothy M Acker

Rose M Santangelo

Jennifer L Hammond

Lisa Warden

Cara Mosley

Bharat Ramkrishna Lagu

Christopher MacNevin

Ashutosh S Jogalekar

Matthew Epplin

Zhongxing Liang

Yung-Chi Cheng

John R Carson

Philip Michael Pitis

Cynthia Anne Maryanoff

Richard J Carmosin

Lanny Steven Liebeskind

Matthew John Fuchter

Robert B Raffa

Jan Pohl

Richard K Plemper

Bodo Scheiper

Simak Ali

Vasken Paragamian

Bryan D Cox

Qi Shi

Jan Brackow

Anthony Prosser

Yesim Altas

David D Mott

James J Doherty, Jr

José D Soria

Robert James Wilson

Huy Hoang Nguyen

Michelle Bora Kim

Valarie Truax

Praseeda Mullasseril

Eva M Schmelz

Thomas Kaiser

Sommer Zimmerman

Kapil N Bhalla

John DiRaddo

Eric James Miller

This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.

Progesterone analogs and uses related thereto

Compounds that selectively inhibit GluN2B-containing N-methyl-D-aspartic acid receptors (NM/DARs) are disclosed. In some cases, the compounds selectively target GluN2B over GluN2A, GluN2C, and/or GluN2D. Generally, the compounds possess an enhanced potency to GluN2B at a pH that is more acidic compared to the physiological pH. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a condition, disorder or disease using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary conditions, disorders, and diseases relevant to this disclosure include stroke, subarachnoid hemorrhage, cerebral ischemia, cerebral vasospasm, hypoxia, acute CNS injury, spinal cord injury, traumatic brain injury, coronary artery bypass graft, persistent or chronic cough, substance abuse disorder, opiate withdrawal, opiate tolerance, bipolar disorder, suicidal ideation, pain, fibromyalgia, depression, postpartum depression, resting tremor, dementia, epilepsy, seizure disorder, movement disorder, and neurodegenerative disease.

GluN2B-subunit selective antagonists of the N-methyl-D-aspartate receptors with enhanced potency at acidic pH

This disclosure relates to progesterone phosphate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic brain injury or stroke.

Progesterone phosphate analogs and uses related thereto

This disclosure related to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is a compound having the formula:

Substituted nucleosides and nucleotides for treating viral infections

The present disclosure relates to compounds for the use of treating neurodegenerative diseases and, in particular, to compounds targeting the Abelson non-tyrosine kinase (c-Abl) protein for such treatment. The neurological disorders and conditions include Parkinson's disease, Alzheimer's disease and the like. It also relates to pharmaceutical compositions and methods of treatment of such neurological disorders involving the c-Abl protein kinase.

Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases

A compound according to Formula (I) or salts or prodrugs thereof and pharmaceutical formulations comprising the compound are provided herein for the treatment of neurological disorders. The disorders may include providing neuroprotection, preventing neurodegeneration, treating neuropathic pain or treating schizophrenia, psychoses or depression. Furthermore, the compounds may be used in combination with another active ingredient.

GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor

This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.

Lipid disulfide prodrugs and uses related thereto

This disclosure relates to pyrazoline dihydroquinolone derivatives, pharmaceutical compositions, and uses. In certain embodiments, the compounds are selective NMDA receptor inhibitors and are useful in therapeutic methods related thereto. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a compound of the following formula:

Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses

This disclosure relates to compounds according to Formula (I), salts, prodrugs and pharmaceutical formulation comprising the compound are provided herein for the treatment of CXCR4 and CCR5 related conditions. The conditions may include viral infections, abnormal cellular proliferation, retinal degeneration and inflammatory diseases, or the compounds may be used as immunostimulants or immunosuppressants. Furthermore, the compounds may be used in combination with another active ingredient selected from an antiviral agent or chemotherapeutic agent.

Pan-tropic entry inhibitors

Disclosed are acyclic nucleoside prodrugs with improved metabolic stability and oral bioavailability. In general, the prodrugs are derivatives of acyclic nucleoside phosphonates containing a lipid-like moiety that can increase oral absorption and subsequent stability in the liver and plasma. Preferably, the lipid-like moiety can resist enzyme-mediated ω-oxidation, such as ω-oxidation catalyzed by cytochrome P450 enzymes. Also disclosed are pharmaceutical formulations of the acyclic nucleoside prodrugs. The acyclic nucleoside prodrugs and pharmaceutical formulations thereof can be used to treat viral infections, such as HIV infections, and/or viral-associated cancer, such as HPV-associated cancers.

Nucleoside prodrugs and uses related thereto

Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.

Inhibitors of RSV replication and applications thereof

The disclosure relates thieno[2,3-d]pyrimidin-4-one derivatives as modulators of NMDA receptors and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing conditions related to cognition, typically prevention or treatment of neurological conditions related to the NMDA receptor.

Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto

This disclosure relates therapeutic compositions containing a compound of Formula Im: or a pharmaceutically acceptable salt thereof, wherein Ris as defined herein.

Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections

This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substitutents are disclosed herein.

Growing community of inventors

Atlanta, GA, United States of America

Dennis C Liotta